RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial

Inclusion Criteria:

• Participants diagnosed with ALS according to the Lighthouse II protocol whocompleted the Lighthouse II trial.

• Participants taking Riluzole must be on a stable dose.

• Participants taking taurursodiol supplements (TUDCA) can participate in this trialif the supplement does not contain sodium phenylbutyrate.

• Women must not become pregnant (e.g., post-menopausal, surgically sterile, usinghighly effective birth control methods or not having potentially reproductive sex)for the duration of the study plus five days; and women of childbearing potentialmust have a negative urine pregnancy test at baseline and be non-lactating.

• For participants taking antacids (regularly or as required), participant is willingand able to avoid taking antacids for at least 6 hours before and 2 hours after theTriumeq dose.

• Capable of providing informed consent and complying with the trial procedures.

Exclusion Criteria:

• In the Principal Investigator's opinion, the participant is unlikely to be compliantwith the study drug dosing.

• People who are HLA-B*5701 positive.

• Presence of HIV antibodies at screening

• Presence of Hepatitis C antibodies at screening unless participants have hadeffective treatment for Hepatitis C

• Presence of Hepatitis B core or surface antigen at screening

• Known hypersensitivity to Dolutegravir, Abacavir or Lamivudine, or to any of theexcipients.

• Moderate to severe hepatic impairment, as defined by local clinical guidelines.

• Participation in any other investigational drug trial or using anotherinvestigational drug within 5 half-lives of that drug.

• Use of NIV ≥22 h per day or having a tracheostomy

• Clinically significant history of unstable or severe cardiac, oncological,psychiatric, hepatic, or renal disease or other medically significant illness

• Taking medication contraindicated with Triumeq: Dofetilide or Fampridine (dalfampridine)